



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

VARIATION TO BINDING TERM SHEET IN RELATION TO STRATEGIC PARTNERSHIP BETWEEN THE COMPANY AND ENGENCE PTY LIMITED

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

The Board of Directors (the **"Board"** or **"Directors"**) of Singapore Institute of Advanced Medicine Holdings Ltd. (the **"Company"** and together with its subsidiaries, the **"Group"**) refers to the Company's announcements dated 6 June 2024 and 5 September 2024 (collectively, the **"Announcements"**) relating to the binding Term Sheet between the Company and EnGeneIC Pty Limited (**"EnGeneIC"**) relating to the Parties' intentions to explore a Strategic Partnership in relation to the manufacture and distribution of EDV-based Products and the development of EDV-based Theranostics, and the subsequent variation to the Term Sheet by way of a variation letter dated 4 September 2024 (**"1st Variation Letter"**).

The Board wishes to update that, subsequent to the Term Sheet (as varied by the 1st Variation Letter), there have been further positive developments in the application of EnGeneIC's proprietary technology platform, EnGeneIC Dream Vector, resulting in potential changes to the scope of the Company's involvement in the Strategic Partnership, particularly regarding the potential to include EDV-based theranostics and boron capture therapy.

Consequently, the Parties have, by way of a variation letter dated 2 December 2024 (**"2nd Variation Letter"**), mutually agreed with effect from 2 December 2024, on an extension of the period for Parties to work towards entering into a Definitive Agreement to 60 days commencing from the date of the 2nd Variation Letter

Save for the above, all other terms and conditions of the Term Sheet (as varied by the 1st Variation Letter) remain unchanged.

The Company will keep shareholders updated on any material developments in relation to the Term Sheet (as varied by the 1st Variation Letter and the 2nd Variation Letter) by way of announcements as and when appropriate.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
3 December 2024

Singapore Institute of Advanced Medicine Holdings Ltd. (the **"Company"**) was listed on Catalist of the Singapore Exchange Securities Trading Limited (**"SGX-ST"**) on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the **"Sponsor"**).

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.